1.
Leuk Res Rep
; 4(1): 31, 2015.
Article
in English
| MEDLINE
| ID: mdl-26101742
ABSTRACT
[This corrects the article DOI: 10.1016/j.lrr.2014.05.003.].
2.
Leuk Res Rep
; 3(2): 73-5, 2014.
Article
in English
| MEDLINE
| ID: mdl-25379406
ABSTRACT
We report a 55 year old woman with post-ET PV for 12 years, who experienced resolution of severe constitutional symptoms within 3 days, a marked reduction in splenomegaly and a rapid decline in the JAK2V617F allele burden during combination therapy with interferon-alpha2a and ruxolitinib. Within 4 weeks the patient achieved complete hematological remission with normalization of peripheral blood counts and within 10 months the JAK2V617F-allele burden was reduced from 90% to 28%. Such a rapid decline in the JAK2V617F allele burden is highly unusual in PV-patients during low-dose IFN-alpha2 monotherapy and this finding warrants a prospective study with combination therapy.